LiveSpo(R) NAVAX Nasal-Spray Probiotics: A New Approach in Supporting the Treatment of Rhinosinusitis and Otitis Media
The findings from the clinical study, conducted Thai Binh University of Medicine and Pharmacy in collaboration with other institutions, was published on January 27, 2025, in Scientific Reports-Nature, a renowned journal under the Nature Portfolio (UK). The results demonstrated significant effectiveness in children within just 3-7 days of use. Additionally, data also showed positive improvements in adults, highlighting the product's potential for broader application in the future.
The study was carried out from November 2023 to December 2024 with the participation of 126 patients, including both children and adults. Among children with acute rhinosinusitis and perforated acute otitis media, the treatment results were particularly notable: after 3 days of using LiveSpo® NAVAX, nasal congestion decreased by 68%, twice as much as the saline group. After 7 days, 97% of the children had no more nasal discharge, and 100% had no more ear discharge. The concentration of pathogenic bacteria Streptococcus pneumoniae in nasal and ear secretions dropped more than 1,200 times. Importantly, no side effects were recorded during the entire trial - even in children with weakened immune systems.
In the adult group with acute sinusitis, symptoms such as nasal congestion, facial pain, and purulent discharge improved significantly after 3 days of use - with reductions of 53%, 78%, and 61%, respectively. After 7 days, 91% of patients no longer experienced nasal discharge. Laboratory results showed a substantial reduction in pathogenic bacteria: Streptococcus pneumoniae decreased over 380-fold and Haemophilus influenzae decreased over 49,000-fold compared to the Control group receiving physiological saline
According to the research team, the effectiveness of LiveSpo® NAVAX origins from its ability to modulate local inflammatory responses and enhance mucosal immunity through the competitive biological mechanism of spore-forming Bacillus probiotics. Inflammatory markers such as IL-6, IL-8, and TNF-α significantly decreased, while levels of IgA - a key protective antibody at the mucosal surface - increased, contributing to the restoration of the nose and ear's natural defense barrier.
This study not only adds to the growing body of scientific evidence supporting LiveSpo® NAVAX's efficacy in respiratory care but also affirms Vietnam's biomedical research capabilities on the international scientific map. It paves the way for a safe, sustainable respiratory treatment alternative that reduces reliance on antibiotics - especially for vulnerable groups like children.
Dr. Nguyen Hoa Anh, Chairman and Founder of LiveSpo Pharma, shared:"At LiveSpo, we prioritize the research and development of internationally standardized products, combining modern medicine with advanced probiotic technology to deliver safe and effective health solutions for the community - all with a vision of A Future Without Antibiotics."
References:Khieu TH, Le DP, Nguyen BT, Ngo BT, Chu HT, Truong DM, Nguyen HM, Nguyen AH, Pham TD, Van Nguyen AT. Alleviating symptoms of paediatric acute rhinosinusitis and acute otitis media with otorrhea using nasal-spraying Bacillus probiotics: a randomized controlled trial. Sci Rep. 2025 Jan 27;15(1):3410. doi: 10.1038/s41598-025-87372-2. PMID: 39870748; PMCID: PMC11772584.
About LiveSpo Pharma
LiveSpo is an R&D, manufacturing, and distribution brand of Clinically Proven Medical Probiotics, leading in breakthrough technology, rapid effectiveness, and convenience, aiming for "A Future Without Antibiotics".
Our vision: In 2027, LiveSpo will have 1.5 million consumers who use Spore probiotics for digestive and respiratory health instead of antibiotics, with outstanding benefits and customer experiences. Established since 2010 by Dr. Nguyen Hoa Anh (Dr. ANH) and his colleagues, LiveSpo has remained steadfast in its belief that Live Probiotic Spores - Spobiotic - will pave the way to a future without antibiotics for everyone.
Hotline: 1800.088808
Website: LiveSpo.com
Media Contact
anabio.rd2021@gmail.com
SOURCE: LiveSpo
View the original press release on ACCESS Newswire
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
Alzheimer's researchers say targeting brain sugar could help protect against dementia
The brain has a hidden "sugar code" that could lead to better treatments for neurological diseases like Alzheimer's, according to new research. A study recently published in the journal Nature Metabolism found that breaking down glycogen (stored glucose) in the brain could reduce the buildup of toxic proteins linked to the common dementia. This was one of the first studies to show that glycogen may actively influence brain health and disease, according to lead author Dr. Pankaj Kapahi, a professor at the Buck Institute for Research on Aging in California. Two Cancer Drugs Show Promise In Reversing Alzheimer's Devastating Effects "The study began with fruit flies (Drosophila) that were genetically modified to mimic tauopathy, a condition where a protein called tau builds up in the brain, similar to what happens in Alzheimer's disease," Kapahi told Fox News Digital. The flies used in the study were found to have brain damage and shortened lifespans, according to the researcher. Read On The Fox News App To ensure that the results could translate to humans, the research team also studied nerve cells made in the lab from human patient cells carrying tau mutations, as well as postmortem brain samples from people who had Alzheimer's or related conditions, according to a press release. In both the fly and human models, the researchers found increased levels of glycogen (stored glucose) in the brain, as well as signs that glycogen breakdown was impaired, Kapahi told Fox News Digital. This was a surprising discovery, as researchers previously thought glycogen was mainly stored in the muscles and liver. Alzheimer's Risk Could Rise With Specific Sleep Pattern, Experts Warn They also found that the excess glycogen contributed to disease. The tau proteins in the scientists' models interacted with glycogen, blocking it from breaking down, and the nerves lost their ability to ward off cell damage. However, the researchers found they could decrease damage to the fruit flies and human nerves by boosting an enzyme called glycogen phosphorylase (GlyP), which breaks down glycogen. The nerve cells used the glycogen to fight against cell damage, suggesting that the enzymes responsible for breaking down sugar could be promising targets for future therapies. The researchers were also curious whether a restricted diet could improve the flies' brain health. When they reduced the amount of protein in the insects' diet, the flies indeed lived longer and their brain health improved. "We then discovered this improvement was linked to an increase in the breakdown of glycogen," Kapahi said. This led to the study's main finding — that breaking down glycogen in neurons can protect the brain from damage caused by tau buildup. Eating These Common Foods Could Reduce Alzheimer's Risk, Experts Say The scientists also developed a drug using a special molecule called 8-Br-cAMP that replicated similar effects of dietary restriction, the press release noted. The authors clarified that they are not recommending low-protein diets just yet — but said this research could pave the way for dietary or drug-based strategies to help slow Alzheimer's and related diseases. Dr. Michael Okun, a Florida neurologist and medical advisor to the Parkinson's Foundation, was not involved in the study but commented on the significance of the findings. "Instead of funneling sugar into energy-burning processes, the broken-down glycogen seemed to be routed into an antioxidant-producing pathway," Okun, who is also author of "The Parkinson's Plan," told Fox News Digital. "The next step in the process may be mopping up potentially damaging free radicals roaming our brains," he said. Okun also confirmed that dietary restrictions activated a protective brain pathway and boosted the breakdown of brain sugar. "It ultimately reduced damage from the Alzheimer's-related tau protein," he said. The study — which was supported by the National Institutes of Health, as well as the American Federation of Aging Research and other sources — did have some limitations, the experts acknowledged. Click Here To Sign Up For Our Health Newsletter The researchers did not clarify whether breaking down brain glycogen could stop human brain cells from dying, Okun noted. "We don't yet know why glycogen builds up in disease, or whether it's a cause or a result of tau pathology — though our data suggest it may amplify disease progression," Kapahi added. The research was also conducted only on fly and human cell models and has not yet been tested on living humans. "We still don't know if targeting glycogen breakdown will work in human patients — and most importantly, whether it will be a safe approach," Okun said. Alzheimer's disease, the most common form of dementia in the U.S., affects more than seven million people in the U.S., according to the Alzheimer's Association. For more Health articles, visit The neurological disorder affects memory, thinking and behavior. There is no cure for the disease, but some medications can temporarily slow progression and improve quality of article source: Alzheimer's researchers say targeting brain sugar could help protect against dementia Solve the daily Crossword
Miami Herald
8 hours ago
- Miami Herald
enVVeno Medical Participates in a New Virtual Investor "What This Means" Segment to Discuss How President Trump's Recent CVI Diagnosis May Impact the Company
- enVVeno is developing the VenoValve as a potential treatment option for the approximately 2.5 million patients in the U.S. suffering from severe deep Chronic Venous Insufficiency - FDA decision expected in 2H'2025 - Access the "What This Means" segment here IRVINE, CA / ACCESS Newswire / August 4, 2025 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno Medical" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today announced that it participated in a Virtual Investor "What This Means" segment entitled, "enVVeno Medical - Making Veins Work Again - How President Trump's CVI Diagnosis is Raising Awareness." Rob Berman, CEO and Dr. Marc Glickman, CMO of enVVeno Medical discussed the progressive nature of chronic veinous insufficiency and whether President Trump may one day be a candidate for the VenoValve® following U.S. Food and Drug Administration (FDA) approval. The Company estimates that there are approximately 2.5 million patients in the U.S. that could be candidates for the VenoValve. The Company has submitted a pre-market authorization (PMA) application for the VenoValve to the FDA, with a decision anticipated in the second half of 2025. The "What This Means" segment can be accessed here. About CVI Severe deep venous CVI is a serious and debilitating disease that is most often caused by blood clots (deep vein thromboses or DVTs) in the deep veins of the leg. When valves inside of the veins of the leg fail, blood flows in the wrong direction and pools in the lower leg, causing pressure within the veins of the leg to increase (venous hypertension). Symptoms of CVI include leg swelling, pain, edema, and in the most severe cases, recurrent open sores known as venous ulcers. The disease can severely impact everyday functions such as sleeping, bathing, dressing, and walking, and is known to result in high rates of depression and anxiety. There are currently no effective treatments that repair deep venous valve dysfunction, the #1 cause of severe CVI-a disease estimated to cost the U.S. healthcare system in excess of $26 billion each year. About enVVeno Medical Corporation enVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, late clinical-stage medical device Company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of deep venous disease. The Company's lead product, the VenoValve®, is a first-in-class surgical replacement venous valve being developed for the treatment of deep venous Chronic Venous Insufficiency (CVI). The Company is also developing a non-surgical, transcatheter based replacement venous valve for the treatment of deep venous CVI called enVVe®. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the leg, and back to the heart and lungs. The VenoValve is currently being evaluated in the VenoValve U.S. pivotal study and the Company is currently performing the final testing necessary to seek approval for the pivotal trial for enVVe. INVESTOR CONTACT: Jenene Thomas, JTC Team, LLCNVNO@ 824-0775 MEDIA CONTACT:Glenn Silver, FINN 818-8198 SOURCE: enVVeno Medical Corporation
CNET
14 hours ago
- CNET
This Nature App Uses AI to Turn Anyone Into a Wildlife Expert. Here's How to Get Started
When I recently moved, one of the building's standout features was the plethora of different plant species in front of its windows. But not like standard landscaping -- more like drier plants, seemingly native to the area. Curious and fairly incompetent in plant sciences, I looked for help in being able to categorize and understand more about it. That's how I found Seek by iNaturalist, a free app where you take photos of plants, animals and fungi. Artificial intelligence suggests its type -- with human confirmation -- while your input and contributions elevate scientific research. What is Seek and how does it use AI? Founded in 2008 as a master's project from UC Berkeley students, iNaturalist later became a joint initiative between the California Academy of Sciences and the National Geographic Society. It strives to connect people to nature and conservation through crowdsourced data. Today, it contains more than 250 million observations of more than a half-million species. (And I just added seven more in roughly 5 minutes.) Seek by iNaturalist is 100% free thanks to donors who contributed to the platform. It operates as a nonprofit organization that makes all collected data -- with the option to turn it off -- openly accessible to scientists and conservationists worldwide. iNaturalist uses computer vision AI to analyze uploaded photos against a model trained on millions of previous observations. AI is also used on the back end -- it optimizes species recognition accuracy, to display the most relevant photos alongside suggestions and pattern recognition improvements. This helps you distinguish between similar-looking species at home or across your local ecosystems. According to the iNaturalist team, "When you use the AI camera feature on any wild living thing, iNaturalist suggests an identification for what you might be seeing -- whether plant, insect, fungus or other organism." They shared that from there, that photo becomes a useful piece of data for science and conservation. But ultimately, a community of naturalists confirm or correct those AI suggestions. Together, AI and human intelligence help newcomers contribute to biodiversity documentation from their first upload. How to use iNaturalist to spot and categorize nature 1. First search for Seek in your app store of choice and create an account by signing up with email or a social media authenticator. You'll also need to allow camera and location permissions to be able to use the AI's computer vision and accurately detect species. 2. It's best to play around a bit before starting scans. Open the app and tap the camera button -- it's designed to recognize any plant, animal and fungi. I focused solely on plants, as that's what I had readily available. Snap a couple photos or hold the camera button down to snap continuously. Using iNaturalist's AI camera to identify a plant species. Screenshot by CNET As you're testing the camera out, note background images, angles and even lighting, which all play a part in the AI tool's ability to accurately recognize what you've captured. (I had to redo a couple because an attempt to take a birds-eye shot ended up with pictures of my feet.) 3. Next, the AI computer vision will analyze your photo and suggest possible species. This takes no longer than 30 seconds. Here you can also record GPS coordinates and you have the option to add details about behavior, size and other aspects of whatever it is you observed and captured. Beyond this, you can also toggle between privacy options, and select whether it is captive, like a plant, or wild, like natural growth. 4. AI also has suggestions for your species identification, which show up as percentages for accuracy. You can also post your observation -- if geoprivacy is open -- to the community for review by users and experts, like scientists. Once the community confirms your species, your observation becomes scientific data. The point here is that you are part of the collection process for scientists to learn more about species in the world. With your input and the community's approval, you're directly involved in this process. Think of yourself as a bridge between reality and what scientists are constantly trying to understand and improve. The iNaturalist team provided tips for getting the best results, alongside checking out their company guides, or downloading the Seek user guide: treat AI suggestions as a starting point, and engage with other humans; explore information on iNaturalist's database; and be aware that there are more advanced camera suggestions in the iPhone app over the Android app. Should you use iNaturalist? The app is designed like Instagram for nature lovers, with a volunteer process that positions itself as additional help for scientists' discoveries. In my opinion, technology that helps connect people to nature and advances scientific understanding is inherently valuable for our planet and future generations. Some of the privacy options available on the iNaturalist Seek app when you upload your observations. iNaturalist / Screenshot by CNET But even though Seek operates globally, with 3.7 million users, the identification accuracy depends heavily on having active expert communities in your region. This means rural or less-populated areas might get slower species confirmations. Additionally, the topic of AI ethics comes to mind. I asked the iNaturalist team about this. They responded that the location is important for information when correctly identifying species, especially wild ones. Yet they also noted that anyone using iNaturalist can "choose to obscure the precise locations of observations to protect their privacy" and that you can use the AI identification feature without creating an account or posting publicly. The iNaturalist team also regularly updates the Privacy Policy in support of the well-being of the community. The main goal is to create an open biodiversity dataset that can be used to protect nature around the world. Overall, Seek by iNaturalist is a great way to educate yourself and contribute to multiple versions of ecosystems in the process while learning and sharing your findings along the way -- or, as the iNaturalist team shared, a "virtuous cycle of collective effort and improvement, built on community trust and benefit in service of helping people connect with nature and biodiversity worldwide."
